Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplant...

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: British Journal of Haematology
Personen und Körperschaften: Baron, Frédéric, Frère, Pascale, Fillet, Georges, Beguin, Yves
In: British Journal of Haematology, 123, 2003, 1, S. 103-105
Format: E-Article
Sprache: Englisch
veröffentlicht:
Wiley
Schlagwörter:
Hematology
author_facet Baron, Frédéric
Frère, Pascale
Fillet, Georges
Beguin, Yves
Baron, Frédéric
Frère, Pascale
Fillet, Georges
Beguin, Yves
author Baron, Frédéric
Frère, Pascale
Fillet, Georges
Beguin, Yves
spellingShingle Baron, Frédéric
Frère, Pascale
Fillet, Georges
Beguin, Yves
British Journal of Haematology
Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
Hematology
author_sort baron, frédéric
spelling Baron, Frédéric Frère, Pascale Fillet, Georges Beguin, Yves 0007-1048 1365-2141 Wiley Hematology http://dx.doi.org/10.1046/j.1365-2141.2003.04556.x <jats:p><jats:bold>Summary.</jats:bold> We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high‐dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9·5 <jats:italic>±</jats:italic> 1·1 g/dl and 12·5 <jats:italic>±</jats:italic> 0·9 g/dl at the first and second transplant respectively (<jats:italic>P</jats:italic> &lt; 0·001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (<jats:italic>P</jats:italic> &lt; 0·001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.</jats:p> Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion British Journal of Haematology
doi_str_mv 10.1046/j.1365-2141.2003.04556.x
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjE0MS4yMDAzLjA0NTU2Lng
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjE0MS4yMDAzLjA0NTU2Lng
institution DE-Zwi2
DE-D161
DE-Zi4
DE-Gla1
DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
imprint Wiley, 2003
imprint_str_mv Wiley, 2003
issn 0007-1048
1365-2141
issn_str_mv 0007-1048
1365-2141
language English
mega_collection Wiley (CrossRef)
match_str baron2003tandemhighdosetherapyhdtformultiplemyelomarecombinanthumanerythropoietintherapygivenbetweenfirstandsecondhdtallowssecondperipheralbloodstemcelltransplantationwithoutredbloodcelltransfusion
publishDateSort 2003
publisher Wiley
recordtype ai
record_format ai
series British Journal of Haematology
source_id 49
title Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_unstemmed Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_full Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_fullStr Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_full_unstemmed Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_short Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_sort tandem high‐dose therapy (hdt) for multiple myeloma: recombinant human erythropoietin therapy given between first and second hdt allows second peripheral blood stem cell transplantation without red blood cell transfusion
topic Hematology
url http://dx.doi.org/10.1046/j.1365-2141.2003.04556.x
publishDate 2003
physical 103-105
description <jats:p><jats:bold>Summary.</jats:bold> We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high‐dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9·5 <jats:italic>±</jats:italic> 1·1 g/dl and 12·5 <jats:italic>±</jats:italic> 0·9 g/dl at the first and second transplant respectively (<jats:italic>P</jats:italic> &lt; 0·001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (<jats:italic>P</jats:italic> &lt; 0·001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.</jats:p>
container_issue 1
container_start_page 103
container_title British Journal of Haematology
container_volume 123
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792338262406201347
geogr_code not assigned
last_indexed 2024-03-01T15:29:26.62Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Tandem+high%E2%80%90dose+therapy+%28HDT%29+for+multiple+myeloma%3A+recombinant+human+erythropoietin+therapy+given+between+first+and+second+HDT+allows+second+peripheral+blood+stem+cell+transplantation+without+red+blood+cell+transfusion&rft.date=2003-10-01&genre=article&issn=1365-2141&volume=123&issue=1&spage=103&epage=105&pages=103-105&jtitle=British+Journal+of+Haematology&atitle=Tandem+high%E2%80%90dose+therapy+%28HDT%29+for+multiple+myeloma%3A+recombinant+human+erythropoietin+therapy+given+between+first+and+second+HDT+allows+second+peripheral+blood+stem+cell+transplantation+without+red+blood+cell+transfusion&aulast=Beguin&aufirst=Yves&rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2003.04556.x&rft.language%5B0%5D=eng
SOLR
_version_ 1792338262406201347
author Baron, Frédéric, Frère, Pascale, Fillet, Georges, Beguin, Yves
author_facet Baron, Frédéric, Frère, Pascale, Fillet, Georges, Beguin, Yves, Baron, Frédéric, Frère, Pascale, Fillet, Georges, Beguin, Yves
author_sort baron, frédéric
container_issue 1
container_start_page 103
container_title British Journal of Haematology
container_volume 123
description <jats:p><jats:bold>Summary.</jats:bold> We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high‐dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9·5 <jats:italic>±</jats:italic> 1·1 g/dl and 12·5 <jats:italic>±</jats:italic> 0·9 g/dl at the first and second transplant respectively (<jats:italic>P</jats:italic> &lt; 0·001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (<jats:italic>P</jats:italic> &lt; 0·001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.</jats:p>
doi_str_mv 10.1046/j.1365-2141.2003.04556.x
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjEzNjUtMjE0MS4yMDAzLjA0NTU2Lng
imprint Wiley, 2003
imprint_str_mv Wiley, 2003
institution DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1
issn 0007-1048, 1365-2141
issn_str_mv 0007-1048, 1365-2141
language English
last_indexed 2024-03-01T15:29:26.62Z
match_str baron2003tandemhighdosetherapyhdtformultiplemyelomarecombinanthumanerythropoietintherapygivenbetweenfirstandsecondhdtallowssecondperipheralbloodstemcelltransplantationwithoutredbloodcelltransfusion
mega_collection Wiley (CrossRef)
physical 103-105
publishDate 2003
publishDateSort 2003
publisher Wiley
record_format ai
recordtype ai
series British Journal of Haematology
source_id 49
spelling Baron, Frédéric Frère, Pascale Fillet, Georges Beguin, Yves 0007-1048 1365-2141 Wiley Hematology http://dx.doi.org/10.1046/j.1365-2141.2003.04556.x <jats:p><jats:bold>Summary.</jats:bold> We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high‐dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9·5 <jats:italic>±</jats:italic> 1·1 g/dl and 12·5 <jats:italic>±</jats:italic> 0·9 g/dl at the first and second transplant respectively (<jats:italic>P</jats:italic> &lt; 0·001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (<jats:italic>P</jats:italic> &lt; 0·001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.</jats:p> Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion British Journal of Haematology
spellingShingle Baron, Frédéric, Frère, Pascale, Fillet, Georges, Beguin, Yves, British Journal of Haematology, Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion, Hematology
title Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_full Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_fullStr Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_full_unstemmed Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_short Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_sort tandem high‐dose therapy (hdt) for multiple myeloma: recombinant human erythropoietin therapy given between first and second hdt allows second peripheral blood stem cell transplantation without red blood cell transfusion
title_unstemmed Tandem high‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion
topic Hematology
url http://dx.doi.org/10.1046/j.1365-2141.2003.04556.x